Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ERAS
$13.4865
$
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
1.221
Average Volume
Market Cap
Last Dividend
CIK
0001761918
ISIN
US29479A1088
CUSIP
29479A108
CEO
Jonathan E. Lim
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
103
IPO Date
2021-07-16
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled “Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof. | GlobeNewsWire | 2026-02-24 08:00:00 |
| Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat | Erasca (NASDAQ: ERAS) executives highlighted early clinical signals and the company's strategy to differentiate its RAS-focused pipeline during a Guggenheim fireside chat featuring CEO Jonathan Lim and CFO David Chacko. How Erasca sees differentiation in the pan-RAS field Chacko framed the current pan-RAS landscape around Revolution Medicines' RMC-6236, calling it "a breakthrough for the whole RAS, | Defense World | 2026-02-15 04:44:56 |
| Stock Traders Buy Large Volume of Erasca Call Options (NASDAQ:ERAS) | Erasca, Inc. (NASDAQ: ERAS - Get Free Report) saw some unusual options trading on Wednesday. Investors bought 4,075 call options on the stock. This is an increase of approximately 104% compared to the typical daily volume of 2,001 call options. Insiders Place Their Bets In other news, General Counsel Ebun Garner sold 120,000 shares of Erasca | Defense World | 2026-02-12 04:34:55 |
| Erasca to Present at Upcoming Conferences in February | SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026) Location: New York, NY Format: Fireside Chat Date and Time: Thursday, February 12, 1:00 pm Eastern Time Oppenheimer 36 th Annual Healthcare Life Sciences Conference (February 25-26, 2026) Location: Virtual Format: Fireside Chat Date and Time: Thursday, February 26, 11:20 am Eastern Time A live audio webcast of the events will be available online at Erasca.com/events. | GlobeNewsWire | 2026-02-05 08:00:00 |
| Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? | Erasca Inc. (NASDAQ: ERAS) stock is trading lower on Monday, though there is no news to justify the movement. | Benzinga | 2026-01-26 07:52:36 |
| Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $10.00 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $258.8 million. All of the shares of common stock sold in the public offering were sold by Erasca. | GlobeNewsWire | 2026-01-23 16:01:00 |
| Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to the satisfaction of customary closing conditions. | GlobeNewsWire | 2026-01-21 20:54:00 |
| Erasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short Interest | Erasca, Inc. (NASDAQ: ERAS - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 20,487,523 shares, a growth of 20.8% from the December 15th total of 16,962,442 shares. Based on an average trading volume of 2,652,389 shares, the short-interest ratio is presently 7.7 days. | Defense World | 2026-01-21 03:20:55 |
| Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. | GlobeNewsWire | 2026-01-20 16:01:00 |
| Erasca Stock Surges 42% in a Week: Here's What You Should Know | ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment. | Zacks Investment Research | 2026-01-16 10:10:47 |
| David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 | The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise. | Benzinga | 2026-01-15 16:12:14 |
| Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff | /PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion | PRNewsWire | 2026-01-14 10:52:00 |
| Erasca Insider Sells $671K as Stock Jumps 189% This Past Year | Erasca's general counsel and corporate secretary sold 120,000 shares of the biotech for $670,800 in gross proceeds on Jan. 7. The sale resulted from an option exercise with shares immediately sold; no indirect holdings or gifts were involved. | The Motley Fool | 2026-01-13 14:53:29 |
| Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation | GlobeNewsWire | 2026-01-12 08:00:00 |
| Ebun Garner Sells 120,000 Shares of Erasca (NASDAQ:ERAS) Stock | Erasca, Inc. (NASDAQ: ERAS - Get Free Report) General Counsel Ebun Garner sold 120,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the sale, the general counsel directly owned 25,076 | Defense World | 2026-01-10 05:22:47 |
| What's Going With Cancer Biotech Erasca Stock On Thursday? | Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. | Benzinga | 2026-01-08 13:21:11 |
| Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. | GlobeNewsWire | 2026-01-06 08:00:00 |
| Hallador Energy Advances Expansion into Natural Gas Power Generation through ERAS Application | TERRE HAUTE, Ind., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that the Company has finalized its application into the Expedited Resource Addition Study (ERAS) program and has made deposits totaling approximately $13 million as required under the application process. | GlobeNewsWire | 2025-12-16 16:05:00 |
| Erasca to Present at the 8th Annual Evercore Healthcare Conference | SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in one-on-one investor meetings. | GlobeNewsWire | 2025-11-25 09:08:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-29 | 2026-01-29 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 424B5 | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 424B5 | 2026-01-20 | 2026-01-20 | View Filing |
| SC 13G | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| SC 13G | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G | 2025-08-13 | 2025-08-13 | View Filing |
| S-3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| SC 13G/A | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2025-01-02 | 2025-01-02 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-10-29 | 2024-10-29 | View Filing |
| SC 13G | 2024-10-24 | 2024-10-24 | View Filing |
| 8-K | 2024-10-24 | 2024-10-24 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-06-24 | 2024-06-24 | View Filing |
| 8-K | 2024-06-24 | 2024-06-24 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| SC 13G | 2024-05-31 | 2024-05-31 | View Filing |
| SC 13G | 2024-05-29 | 2024-05-29 | View Filing |
| SC 13G | 2024-05-28 | 2024-05-28 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 424B5 | 2024-05-17 | 2024-05-17 | View Filing |
| 8-K | 2024-05-17 | 2024-05-17 | View Filing |
| EFFECT | 2024-05-17 | 2024-05-17 | View Filing |
| 8-K | 2024-05-16 | 2024-05-16 | View Filing |
| S-3 | 2024-05-09 | 2024-05-09 | View Filing |
| S-8 | 2024-05-09 | 2024-05-09 | View Filing |
| 10-Q | 2024-05-08 | 2024-05-08 | View Filing |
| 8-K | 2024-05-08 | 2024-05-08 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-03-28 | 2024-03-28 | View Filing |
| 10-K | 2024-03-27 | 2024-03-27 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 52.72% | 1 | 719 | 0.03 | 0.08 | 36.67 |
| Williams PercentR Strategy | 44.80% | 0.99 | 337 | 0.05 | 0.15 | 28.75 |
| Adaptive Wave | 43.76% | 2.03 | 3 | 0.03 | 0.07 | 27.71 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |